{"nctId":"NCT01369329","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)","startDateStruct":{"date":"2011-07"},"conditions":["Crohn's Disease","IBD","Colitis","Inflammatory Bowel Disease"],"count":769,"armGroups":[{"label":"001","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Group 1: Placebo"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Group 2 ustekinumab 130 mg"]},{"label":"003","type":"EXPERIMENTAL","interventionNames":["Drug: Group 3: ustekinumab approximately 6 mg/kg"]}],"interventions":[{"name":"Group 2 ustekinumab 130 mg","otherNames":[]},{"name":"Group 3: ustekinumab approximately 6 mg/kg","otherNames":[]},{"name":"Group 1: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy\n* Have active Crohn's disease, defined as a baseline Crohn's Disease Activity Index (CDAI) score of \\>= 220 and \\<= 450\n* Have received infliximab, adalimumab, or certolizumab pegol at a dose approved for the treatment of Crohn disease and did not respond initially (ie, primary nonresponse)\n* Or responded initially but then lost response with continued therapy (ie, secondary nonresponse)\n* Or were intolerant to the medication\n* Have screening laboratory test results within protocol-specified parameters.\n\nExclusion Criteria:\n\n* Patients who have had any kind of bowel resection within 6 months\n* Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent\n* Patients who have received infliximab, adalimumab or certolizumab pegol \\< = 8 weeks before the first administration of study drug\n* Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug\n* Patients with a history of or ongoing chronic or recurrent infectious disease\n* Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Clinical Response at Week 6","description":"Clinical response at Week 6 was defined as a reduction from baseline in the Crohn's Disease Activity Index score of greater than or equal (\\>=) 100 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). Participants with a baseline CDAI score of \\> = 220 to less than or equal (\\< =) 248 were considered to be in clinical response if a CDAI score of less than (\\<) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Clinical Remission at Week 8","description":"Clinical remission is defined as a CDAI score of less than (\\<) 150 points at Week 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Clinical Response at Week 8","description":"Clinical response at Week 8 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (\\>=) 100 points. Participants with a baseline CDAI score of \\> = 220 to less than or equal (\\< =) 248 were considered to be in clinical response if a CDAI score of less than (\\<) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Crohn's Disease Activity Index (CDAI) 70-point Response at Week 6","description":"70-point response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With CDAI 70-point Response at Week 3","description":"70-point response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":254},"commonTop":["Arthralgia","Headache","Nausea","Pyrexia","Abdominal Pain"]}}}